Raymond F. Schinazi
Raymond F. Schinazi, Ph.D. is the Frances Winship Walters Professor of Pediatrics, Director, Laboratory of Biochemical Pharmacology and Director, HIV Cure Scientific Working Group at Emory University. Dr. Schinazi's Laboratory of Biochemical Pharmacology at Emory develops approaches to treat infections caused by human immunodeficiency viruses, herpesviruses, HBV, HCV, Zika, West Nile, Chikungunya and Dengue virus. These treatments include antiviral agents as well as synthetic, biochemical, pharmacological, and molecular genetic approaches, including molecular modeling and gene therapy. Dr. Schinazi's company, RFS Pharma LLC., merged with Cocrystal Discovery, Inc. in 2014 to form Cocrystal Pharma, Inc. Dr. Schinazi has retired from the Atlanta Department of Veterans Affairs after 35 years of service serving most recently as Senior Research Career Scientist. In addition, Dr. Schinazi currently serves as a Governing Trustee for the Foundation for AIDS Research (amfAR), Director of Brace Pharmaceuticals, Inc., The International Centre for Missing and Exploited Children (ICMEC), and the Global Virus Network (GVN). He is also currently serving as a non-executive Director of Gliknik Inc. and reViral Ltd.
Vice Chairman and Interim Chief Executive Officer
Gary Wilcox has over 35 years of experience in biotech companies including 14 years at Icos Corporation where he played a key role in the development of Cialis as the Executive Vice President of Operations and a member of the board of directors. Prior to that, he served as Vice Chairman, Executive Vice President and a Director of Xoma Corporation. Prior to Xoma, Dr. Wilcox co-founded Ingene Inc. serving as its Chairman, President and CEO prior to the merger of Ingene into Xoma. Dr. Wilcox was a Professor of Microbiology and a member of the Molecular Biology Institute at UCLA for 10 years. He has served on 15 boards of directors including NASDAQ, New York and London stock exchange companies, as well as private technology companies.
David S. Block
David S. Block has served since 2007 as President and Chief Executive Officer of Gliknik Inc., a biopharmaceutical company which he founded to create new therapies for people living with cancer and immune disorders. From 1990 through its successful sale in 2002, Dr. Block held a number of commercial positions at DuPont Merck and DuPont Pharmaceuticals, ultimately as EVP of International Operations. He was subsequently COO of Celera Genomics and CEO of venture-funded Ruxton Pharmaceuticals prior to founding Gliknik. Dr. Block has been an active HIV physician at Johns Hopkins since 1992.
Phillip Frost is the Chairman and CEO of Opko Health, Inc. (NYSE: OPK). Dr. Frost is the former Chairman of the Board of Teva Pharmaceuticals (NYSE: TEVA). In January 2006 Teva acquired IVAX Corporation. Dr. Frost had served as Chairman and CEO of IVAX Corporation since 1987. He has served on the Board of Regents of the Smithsonian Institution, on the Board of Trustees of the University of Miami, as a Trustee of each of the Scripps Research Institutes, and is a director of numerous other organizations.
Jane Hsiao is Vice Chairman and Chief Technical Officer of Opko Health, Inc. She served as the Vice Chairman-Technical Affairs of IVAX from 1995 to January 2006, when Teva acquired IVAX. Dr. Hsiao served as IVAX's chief technical officer from 1996, and as chairman, CEO, and president of IVAX Animal Health, IVAX's veterinary products subsidiary, from 1998. She is a director of Opko Health, Inc. and numerous other organizations.
Steve Rubin is Executive Vice President-Administration and a director of OPKO Health, Inc. Previously, he was Senior Vice President and General Counsel of IVAX. Prior to IVAX, Mr. Rubin was Senior Vice President and General Counsel of Telergy Inc. Mr. Rubin holds a B.A. from Tulane University and a J.D. degree from University of Florida.